Logo Logo Logo Logo Logo
  • COMPANY
    • About Us
    • Senior Management Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • Contact Us
  • TECHNOLOGIES
    • OPTIREACH Technology
    • Antibody Fragment Technology
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
    • OCS-05 Glaucoma
  • NEWS
    • Press releases
    • Articles
  • CAREERS
  • COMPANY

    • About Us
    • Senior Management Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • Contact Us
  • TECHNOLOGIES

    • OPTIREACH Technology
    • Antibody Fragment Technology
  • PIPELINE

    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
    • OCS-05 Glaucoma
  • NEWS

    • Press releases
    • Articles
  • CAREERS
Oculis appoints Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board

...

25 September, 2018
Oculis elects Anthony Rosenberg David A. Weber to its Board of Directors
19 September, 2018
Oculis Raises CHF20 million in a Series B Financing Round to Advance Treatments
01 January, 2018
Prof. Stefansson awarded Peter Watson prize and chair of Cambridge Ophtha. symposium
27 September, 2017
ARVO 2017 – two poster presentations
12 May, 2017
Contact us

Oculis Switzerland
Corporate Headquarters
EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne
Switzerland

+41 21 711 3970

 

info@oculis.com

Copyright © 2022 Oculis SA.

 

    © Oculis – Privacy Policy – Terms of Use  – Cookie Policy    

    © L’autreagence 2019 – 2022